Scarcity premium: the thing the company sells is becoming harder to get, and management is letting the shortage do the s
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that what the company sells is becoming harder for buyers to obtain, and that management is allowing that tightening to work in its favor. The transcript is about Arrowhead Pharmaceuticals, a biotech company developing RNAi therapeutics. They have various drug candidates in clinical trials. The question is about availability of their product/service/capacity etc. In biotech, the "product" is the drug candidates, but they are not yet on the market. The company is developing drugs, not selling them yet. The concept of "buyers" would be patients or partners? They have partnerships with other companies (Takeda, Amgen, etc.) for licensing. But the question is about the company's own product becoming harder to obtain. Since they are a development-stage company, they don't have commercial products yet. They are conducting clinical trials. The scarcity might refer to capacity in manufacturing? They mention capital expenditures for GMP manufacturing. But they don't talk about buyers competing for their output. They talk about their pipeline and progress. They mention "20 in '25" plan. They talk about monetizing royalties. There is no mention of availability tightening for buyers. They are not selling a product that is in short supply. They are developing drugs. The only possible interpretation is that they have limited manufacturing capacity? But they don't discuss that as a constraint on buyers. They discuss their own financial resources and partnerships. The question is clearly about a business where the company sells something and buyers are finding it harder to get. This doesn't apply to a clinical-stage biotech. So the answer is NO. We need to be careful: The transcript might have some mention of "supply" or "capacity" but it's about their own manufacturing expansion. They say "capital expenditures up to $200 million as we near completion on our footprint expansion projects, including GMP manufacturing." That is about adding capacity, not scarcity. They don't say that buyers are waiting. They don't mention any shortage of their product. They are not selling anything yet. So the answer is NO. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| STM | STMicroelectronics NV | Q3 2018 | 2018-10-24 | C+ |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
LEGH · Q4 2023 → YESThe question is: Does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — availability tightening — AND that management is allowing that tightening to work in the c...YES The transcript shows management explicitly holding production levels steady to build backlog rather than ramping output, while continuing to hold pricing levels. Duncan Bates states: “We have held pricing levels and held production levels as we continue to build a backlog across the manufacturing plants” and later “we decided, hey, let's keep production where it is and keep building the backlog.
STM · Q3 2018 → YESThe question is: Does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — availability tightening — AND that management is allowing that tightening to work in the c...YES The transcript shows management describing current shortages and a "stretched supply chain" for their own products (especially Automotive and Power Discrete), with backlogs confirming demand outrunning availability. They explicitly note pricing upside from the fractured supply situation in Power and treat the tightness as a positive dynamic rather than an urgent problem to fix.
ALL · Q3 2023 → YESThe question is: Does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — availability tightening — AND that management is allowing that tightening to work in the c...YES The transcript shows management explicitly restricting new business growth in unprofitable states (California, New York, New Jersey down 75% in new applications) and describing this as part of the profit improvement plan that is working in their favor by improving margins and allowing selective removal of restrictions only where target returns are achieved.